IPO - Profile

Summary

We are a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. To date, we have dosed over 600 cancer patients with our More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$26.00 9,900,000 Positive High 33.4%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • KPMG LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 03 Feb, 2021

Offer 05 Feb, 2021

Look Ahead

Lock Up Expiry Aug 05, 2021

IPO Terms

Offer Price $26.00
Offer Size 9M

Market Sentiments

Stock Price